Cargando…

Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders

BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pospiskova, Jana, Smolej, Lukas, Belada, David, Simkovic, Martin, Motyckova, Monika, Sykorova, Alice, Stepankova, Pavla, Zak, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327395/
https://www.ncbi.nlm.nih.gov/pubmed/30626415
http://dx.doi.org/10.1186/s13023-018-0991-3
_version_ 1783386456375427072
author Pospiskova, Jana
Smolej, Lukas
Belada, David
Simkovic, Martin
Motyckova, Monika
Sykorova, Alice
Stepankova, Pavla
Zak, Pavel
author_facet Pospiskova, Jana
Smolej, Lukas
Belada, David
Simkovic, Martin
Motyckova, Monika
Sykorova, Alice
Stepankova, Pavla
Zak, Pavel
author_sort Pospiskova, Jana
collection PubMed
description BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. CONCLUSION: Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax.
format Online
Article
Text
id pubmed-6327395
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63273952019-01-15 Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders Pospiskova, Jana Smolej, Lukas Belada, David Simkovic, Martin Motyckova, Monika Sykorova, Alice Stepankova, Pavla Zak, Pavel Orphanet J Rare Dis Research BACKGROUND: Chylothorax is a rare condition which can be associated with malignant lymphoproliferative disorders (LPDs). We retrospectively analyzed the results of the conservative treatment of 10 patients with persistent non-traumatic malignant chylothorax. RESULTS: Conservative treatment lead to a decline of chylothorax after mean of 66 days and consisted of the treatment of the underlying disease and of simultaneous long-term supportive care (drainage of the thoracic cavity, dietary measures and nutrition management). In most cases (80%), chylothorax disappeared only after a successful therapeutic response of the underlying disease. Low-dose radiotherapy had very good effects in two patients. CONCLUSION: Conservative treatment of malignant chylothorax can be considered a suitable method. Based on our results, successful treatment of the lymphoproliferative disorder seems to be a very important factor for the disappearance of chylothorax. BioMed Central 2019-01-09 /pmc/articles/PMC6327395/ /pubmed/30626415 http://dx.doi.org/10.1186/s13023-018-0991-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pospiskova, Jana
Smolej, Lukas
Belada, David
Simkovic, Martin
Motyckova, Monika
Sykorova, Alice
Stepankova, Pavla
Zak, Pavel
Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title_full Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title_fullStr Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title_full_unstemmed Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title_short Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
title_sort experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327395/
https://www.ncbi.nlm.nih.gov/pubmed/30626415
http://dx.doi.org/10.1186/s13023-018-0991-3
work_keys_str_mv AT pospiskovajana experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT smolejlukas experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT beladadavid experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT simkovicmartin experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT motyckovamonika experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT sykorovaalice experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT stepankovapavla experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders
AT zakpavel experiencesinthetreatmentofrefractorychylothoraxassociatedwithlymphoproliferativedisorders